NGM
333 Oyster Point Blvd, South San Francisco, CA, 94080, United States
Overview
NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 7
Sector focus
- Biopharma
- Biotechnology
- Genetics
- Medical
Investment portfolio
- Alphacruncher
Participated · Equity · Mar 2022
Alphacruncher offers Nuvolos, an education and research cloud workspace product. Nuvolos bridges the gap between abstract concepts and everyday life by enabling teachers and students to use actual data and hands-on experience in secure, browser-based, scalable workspaces. The platform is designed to drive student engagement, collaboration and skill development, including coding, problem-solving, creativity, and teamwork. Alphacruncher also positions Nuvolos as a research workspace, giving scientific researchers access to storage and cloud computing power for collaborative scientific discovery. The company currently operates in the DACH region and plans to use recent funding to roll Nuvolos out globally. Alphacruncher raised €1.45 million to support that expansion.